Sellas Life Sciences has achieved the 80th event in its Phase 3 REGAL trial of Galinpepimut-S for acute myeloid leukemia. The trial is designed to measure the drug's efficacy, with preliminary results anticipated this quarter. Analysts caution that prolonged trial durations may enhance the likelihood of failure. The company continues to track the trial's progress closely, with updates projected as the trial advances. The REGAL trial is a key step in the development of Galinpepimut-S, which has shown encouraging results in previous phases. Sellas Life Sciences remains committed on advancing the drug through the regulatory process, with the goal of bringing a potential treatment to patients with acute myeloid leukemia. The company's thoughtful approach to clinical trials and data analysis is highly regarded in the industry, and investors are following the trial's outcome with interest.